Low-dose GLP-1 tapering may sustain weight loss, study suggests
A small Scripps Health study followed 30 patients who reduced their GLP-1 medications after reaching weight-loss plateaus. Many kept their BMI, blood pressure, cholesterol and blood sugar improvements with dosing as infrequent as about every two weeks, though a few regained some weight. While promising for reducing treatment burden and costs, the findings are preliminary and require larger randomized trials to confirm generalizability.
